Xcout IntelCellect Biotechnology competitors & alternatives
The 12 closest competitors and alternatives to Cellect Biotechnology among biotechnology companies — ranked by similarity to what Cellect Biotechnology actually does, not by market-cap band.
Subscribe to see Cellect Biotechnology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Cellect Biotechnology
Cellect Biotechnology Ltd. was an Israeli biotechnology company developing cell-selection and regenerative-medicine technologies, including its ApoGraft platform for enriching stem cells from bone marrow or other cell sources. Its products were intended primarily for clinical and research applications involving hematopoietic stem-cell transplantation and cell-based therapies.
Cellect Biotechnology at a glance
Cellect Biotechnology is a biotechnology company headquartered in Israel. It has raised at least $11.3M across the 3 funding rounds on record. Its most recent funding round raised $3M in October 2020.
Cellect Biotechnology funding rounds
At least $11.3M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $3M | — | |
| SEC Form D filing | $4M | — | |
| SEC Form D filing | $4.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Cellect Biotechnology competitors
Ranked by semantic similarity — how close each company is to Cellect Biotechnology by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
ImmuneBridge Inc. is a biotechnology company headquartered in San Francisco, California, that develops a hematopoietic stem cell (HSC) expansion and differentiation platform.
Biotech
Genetix Biotherapeutics develops and delivers one-time, curative genetic therapies for patients suffering from rare, severe genetic diseases such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The company utilizes patients' own blood stem cells, modifying them outside the body to correct underlying genetic defects and restore normal function. It serves patients, families, and healthcare providers by providing these advanced treatments alongside dedicated clinical support and research programs.
Similar biotechnology company
Junten Bio Co. Ltd. is a Japanese pharmaceutical and biotechnology corporation headquartered in Tokyo, specializing in the research and development of cell and regenerative medicine.
Biotech
StemCyte is a global cord blood banking and regenerative therapeutics company that provides public and private umbilical cord blood and cord tissue preservation services for expectant families. The company processes, tests, and cryopreserves stem cells for family protection and clinical use, and supplies cellular materials for transplants and medical research.
Biotech
StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
Biotech
Medipost Co., Ltd. is a South Korean biotechnology company developing and commercializing stem-cell-based regenerative medicines, including treatments derived from human umbilical cord blood mesenchymal stem cells. It also operates a cord-blood banking business serving expectant parents and families.
Biotech
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
Biotech
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Biotech
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
Biotech
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Similar biotechnology company
Cell Research Corporation is a biotechnology company specializing in umbilical cord lining stem cell technology and banking. The company provides products, services, and contract research related to stem cell applications for wound healing, regenerative medicine, and cosmeceuticals.
Similar biotechnology company
Century Therapeutics is an innovative biotechnology company headquartered in Philadelphia, Pennsylvania. Its mission is to develop allogeneic, iPSC-derived NK and T cell therapies that are designed to be more effective, tolerable, and accessible.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Cellect Biotechnology and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Cellect Biotechnologyand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →